Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVER-CoAd: COVID-19 Vaccine Response and Co-Administration in Rheumatology Patients
NCT05543642Phase 4Terminated
- Sponsor
- Oregon Health & Science University
- Start
- Oct 2022
- Primary completion
- Apr 2025
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of SARS-CoV-2 vaccine, Hepatitis A virus vaccine, diphtheria, tetanus, and acellular pertussis vaccine in coronavirus disease 2019 (COVID-19), hepatitis A (HAV), diphtheria, pertussis, Tetanus, sponsored by Oregon Health & Science University. Started Oct 2022; status: terminated.
02
Drugs
SARS-CoV-2 vaccineHepatitis A virus vaccinediphtheria, tetanus, and acellular pertussis vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)hepatitis A (HAV)diphtheriapertussisTetanus
Beyond the preview
Go deeper on NCT05543642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543642.